Comparison of the everolimus-eluting bioresorbable vascular scaffold versus the everolimus-eluting metallic stent in real-world patients with ST-segment elevation myocardial infarction
Advances in Interventional Cardiology · 2020 · 16 (1) · 49-57
DOI: 10.5114/aic.2020.93912 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advances in Interventional Cardiology, 2020. Verfasst von Piotr Desperak und 6 weiteren Autor:innen. Beteiligte Einrichtung: 3 Department of Cardiology, Silesian Center for Heart Diseases in Zabrze, School of Medicine with the Division of Dentistry in Zabrze, Medical Univer…. Die Arbeit wurde bisher 1-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
INTRODUCTION: Despite the withdrawal of the ABSORB bioresorbable vascular scaffold (BVS) from clinical use, continuous observation of BVS-treated patients is necessary. In the vast majority of clinical trials, patients with ST-segment elevation myocardial infarction (STEMI) were excluded from the analysis. AIM: To compare the early and long-term outcomes of the BVS with the everolimus-eluting metallic stent (EES) in patients with STEMI. MATERIAL AND METHODS: Consecutive patients treated with BVS or EES in our center were screened. For analysis, only patients with STEMI were enrolled. The primary endpoint was a comparison of the target lesion failure at 12 and 24 months. The secondary endpoints encompass occurrence of the patient-oriented cardiovascular endpoint (PoCE), stent thrombosis (ST), device, and procedural success. RESULTS: Between 2012 and 2016, 2,137 patients were hospitalized for STEMI. Of these, 123 patients received the BVS (163 scaffolds; 151 lesions), whereas in 141 patients the EES (203 stents; 176 lesions) was implanted. The median follow-up was 931 ±514 days. The primary endpoint at 12 months occurred in 9.7% in the BVS group and in 8.5% in the EES group (hazard ratio (HR) = 2.61; 95% confidence interval (CI): 0.90-7.56; p = 0.076). At 24 months the incidence of the primary endpoint was 15.2% in the BVS group and 14.9% in the EES group (HR = 2.46; 95% CI: 0.85-7.07; p = 0.095). The rates of PoCE, ST, device, and procedural success were also comparable in both groups. CONCLUSIONS: STEMI patients treated with the BVS showed statistically similar rates of primary and secondary endpoints compared with the EES.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- 3 Department of Cardiology, Silesian Center for Heart Diseases in Zabrze, School of Medicine with the Division of Dentistry in Zabrze, Medical University of Silesia in Katowice, Poland.
- Department of Cardiology, Congenital Heart Diseases and Electrotherapy, Silesian Center for Heart Diseases in Zabrze, School of Medicine with the Division of Dentistry in Zabrze, Medical University of Silesia in Katowic…
Zitieren
APA
Desperak, P., Hawranek, M., Chodór, P. A., Świątkowski, A., Kowalczyk, J., Lekston, A., & Gąsior, M. (2020). Comparison of the everolimus-eluting bioresorbable vascular scaffold versus the everolimus-eluting metallic stent in real-world patients with ST-segment elevation myocardial infarction. Advances in Interventional Cardiology, 16(1), 49-57. https://doi.org/10.5114/aic.2020.93912
Vancouver
Desperak P, Hawranek M, Chodór PA, Świątkowski A, Kowalczyk J, Lekston A, et al. Comparison of the everolimus-eluting bioresorbable vascular scaffold versus the everolimus-eluting metallic stent in real-world patients with ST-segment elevation myocardial infarction. Advances in Interventional Cardiology. 2020;16(1):49-57. doi:10.5114/aic.2020.93912
BibTeX
@article{Desperak2020,
author = {Desperak, Piotr and Hawranek, Michał and Chodór, Piotr A and Świątkowski, Andrzej and Kowalczyk, Jacek and Lekston, Andrzej and Gąsior, Mariusz},
title = {Comparison of the everolimus-eluting bioresorbable vascular scaffold versus the everolimus-eluting metallic stent in real-world patients with ST-segment elevation myocardial infarction},
journal = {Advances in Interventional Cardiology},
year = {2020},
volume = {16},
number = {1},
pages = {49--57},
doi = {10.5114/aic.2020.93912}
}
EUVIMED